Coronavirus disease 19 (COVID-19) is known to manifest itself predominantly with respiratory symptoms. However, previous experiences with this disease and many scientific studies have drawn attention to its neurological manifestations. The link between COVID-19 and many neurological diseases, including Guillain Barré syndrome (GBS), has been pointed out. Although GBS is considered a monophasic disease, its relapses occur in 2-6% of cases. We present the case of a female patient with recurrent GBS caused by COVID-19. Given that 2-6% of patients experience a relapse of GBS, and that the COVID-19 pandemic is recognized as a possible trigger of the relapse, we emphasize the importance of intensive neurological monitoring for patients diagnosed with COVID-19 who have a history of GBS.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10827027 | PMC |
http://dx.doi.org/10.17712/nsj.2023.4.20230012 | DOI Listing |
BMC Infect Dis
January 2025
Instituto de Infectologia Emilio Ribas, São Paulo, SP, Brazil.
Background: Neurological manifestations associated with COVID-19 remain partially described, mainly in low- and middle-income countries where diagnostic tools are limited. To address this, we assembled medical centers in Brazil with the goal of describing neurological syndromes associated with COVID-19 during the first wave of the pandemic.
Methods: From June 1st, 2020 to June 1st, 2021, non-consecutive adult patients with new onset of six neurological syndromes up to 60 days after confirmed COVID-19 were included.
eNeurologicalSci
March 2025
Neurosciences Research Center, Poursina Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
Introduction: Guillain-Barré syndrome (GBS) is an inflammatory disorder of the peripheral nervous system, causing acute flaccid paralysis. There have been occasional reports linking Hepatitis A virus (HAV) to GBS. Here we aimed to evaluate the current literature on the association between GBS and HAV, exploring potential mechanisms and clinical implications.
View Article and Find Full Text PDFBMC Neurol
January 2025
Department of Radiology, School of Medicine, College of Medicine and Health Sciences, Mizan-Tepi University, Mizan-Teferi, Ethiopia.
Background: Malaria is an infectious disease caused by Plasmodium parasites, transmitted to humans by infected female Anopheles mosquitoes. Five Plasmodium species infect humans: P. vivax, P.
View Article and Find Full Text PDFPharmaceuticals (Basel)
January 2025
Department of Paediatrics, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
The introduction of anti-tumor necrosis factor-α (anti-TNF-α) agents, particularly infliximab (IFX) and adalimumab (ADA), has significantly expanded the therapeutic arsenal for inflammatory bowel disease (IBD). While these biologics have demonstrated substantial efficacy, they are associated with a spectrum of potential adverse events (AEs). This study aims to evaluate and document these AEs to facilitate optimal patient selection and monitoring strategies of patients undergoing these therapies.
View Article and Find Full Text PDFBMC Neurol
January 2025
Department of Hematology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Background: Multiple myeloma (MM) with Guillain-Barré syndrome (GBS) is relatively rare, and the specific mechanism is still unclear. The previous infection, surgery, and medication use may have contributed to the occurrence of GBS. The use of bortezomib in patients with MM can easily lead to peripheral neuropathy, which is similar to the symptoms of GBS, making it challenging to diagnose GBS.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!